Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,148 |
Reported balance
After 2026-01-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 22,214 · Balance 69,148 F1: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F2: Includes unvested RSUs. F3: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2036-01-20 | Direct | 16,133 |
Reported balance
After 2026-01-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-20 · Grant · Acquired 16,133 · Balance 16,133 F4: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
F2: Includes unvested RSUs.
F3: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above.
F4: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jun 4, 2026 23:08 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 16,133 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001816242-26-000002 · ownership.xml · derivative · entry 2 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,133 Underlying: Common Stock · 16,133 shares Expires 2036-01-20 F4 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. Read SEC document |
| January 20, 2026 Filed Jun 4, 2026 23:08 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 22,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001816242-26-000002 · ownership.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,148 F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F2 · balance_after: Includes unvested RSUs. F3 · balance_after: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above. Read SEC document |
| January 21, 2025 Filed Jun 5, 2025 20:41 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 4,295 | $0.00 Strike: $8.73 | $0.00 |
DisclosureSEC source: 0000950170-25-082422 · ownership.xml · derivative · entry 2 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,295 Underlying: Common Stock · 4,295 shares Expires 2035-01-21 F4 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025. Read SEC document |
| January 21, 2025 Filed Jun 5, 2025 20:41 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,022 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-082422 · ownership.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,934 F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025. F2 · balance_after: Includes unvested RSUs. F3 · balance_after: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above. Read SEC document |
| December 09, 2024 Filed Jan 29, 2025 21:57 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 486 | $13.15 | $6,390.90 |
DisclosureSEC source: 0000950170-25-010560 · ownership.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,912 F1 · shares: Reflects 2,430 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of the Issuer's common stock and have all the rights and privileges of common stock. F2 · price: The purchase price was converted from A$4.11, using the exchange rate as in effect on the date of the transaction, and reflects the 5:1 consolidation ratio applied in converting CDIs to shares of the Issuer's common stock. F3 · balance_after: Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above. F4 · balance_after: Includes unvested RSUs. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:36 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 3,943 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0000950170-24-070118 · ownership.xml · derivative · entry 2 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,943 Underlying: Common Stock · 1 shares Expires 2034-06-05 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:36 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 9,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-070118 · ownership.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,426 F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date. F2 · balance_after: Includes unvested RSUs. F3 · balance_after: Includes 20,560 of the Issuer's CDIs. The Reporting Person's 20,560 CDIs translate into 4,112 of the shares of Common Stock set forth above. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:34 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 2,646 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001209191-23-035434 · doc4.xml · derivative · entry 2 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,646 Underlying: Common Stock · 2,646 shares Expires 2033-06-06 F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock. F5 · derivative.exercise_date: These Stock Options vest on the date 12 months following the grant date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:34 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 6,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-035434 · doc4.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,226 F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock. F2 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date. F3 · balance_after: Includes unvested RSUs. F4 · balance_after: Includes 20,560 of the Issuer's CDIs. The Reporting Person's 20,560 CDIs translate into 4,112 of the shares of Common Stock set forth above. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 22:24 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 5,395 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0001209191-22-061281 · doc4.xml · derivative · entry 2 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,395 Underlying: Common Stock · 5,395 shares Expires 2032-12-12 F4 · derivative.exercise_date: These Stock Options vest on the date 12 months following the grant date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 22:24 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 12,589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-061281 · doc4.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,051 F1 · price: Represents an award of Restricted Stock Units ("RSUs"), each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date. F2 · balance_after: Includes 20,560 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person's 20,560 CDIs translate into 4,112 of the shares of Common Stock set forth above. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:31 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 2,550 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-21-071257 · doc4.xml · derivative · entry 2 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,550 Underlying: Common Stock · 2,550 shares Expires 2031-12-22 F4 · derivative.exercise_date: These Stock Options vest on the date 12 months following the grant date. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:31 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 4,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-071257 · doc4.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,462 F1 · price: Represents an award of Restricted Stock Units ("RSUs"), each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date. F2 · balance_after: Includes 20,560 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person's 20,560 CDIs translate into 4,112 of the shares of Common Stock set forth above. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 20:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | PurchaseCommon Stock | 1,066 | $17.08 | $18,207.28 |
DisclosureSEC source: 0001209191-21-057037 · doc4.xml · nonDerivative · entry 1 Crowe Suzanne · CIK 0001816242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,112 F1 · shares: Reflects 5,330 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of the Issuer's common stock and have all the rights and privileges of common stock. F2 · price: The purchase price was converted from A$4.72, using the exchange rate as in effect on the date of the transaction, and reflects the 5:1 consolidation ratio applied in converting CDIs to shares of the Issuer's common stock. F3 · balance_after: The Reporting Person holds 20,560 CDIs, which translate into the 4,112 shares of common stock set forth above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.